NAGLAZYME Side Effects

7018615-3 | Dyspnoea, Pneumonia
on Sep 09, 2010 Male patient from BRAZIL , weighting 44.09 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea, pneumonia (What is pneumonia?). Naglazyme dosage: (20 Mg 1x/week Intravenous Drip). During the same period patient was treated with AMOXICILLIN (View Amoxicillin Review and Amoxicillin Label ). Patient was hospitalized.

6970481-8 | Thrombocytopenia
Patient was taking Naglazyme (View Usage). Patient had the following side effects: thrombocytopenia on Aug 24, 2010 from TURKEY Additional patient health information: Male patient , child 5 years of age, weighting 33.07 lb, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: (1 Mg/kg 1x/week Intravenous Drip), (0.5 Mg/kg 1x/week Intravenous Drip). During the same period patient was treated with DIPHENHYDRAMINE HCL (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ).

6907226-3 | Erythema, Hypertension, Infusion Related Reaction, Pruritus, Rash
Adverse event was reported on Jul 20, 2010 by a Female patient taking Naglazyme (View Usage) (Dosage: (4 Vials Intravenous Drip), (20 Mg 1x/week Intravenous Drip)) . Location: BRAZIL , weighting 47.40 lb, After Naglazyme was administered, patient had the following side effects: erythema, hypertension, infusion related reaction, pruritus, rash (What is rash?). During the same period patient was treated with POLARAMINE /00072502/ (View Polaramine /00072502/ Review and Polaramine /00072502/ Label ). Patient was hospitalized.

6864009-0 | Staphylococcal Bacteraemia
on Jul 07, 2010 Female patient from UNITED STATES , weighting 31.31 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: staphylococcal bacteraemia. Naglazyme dosage: (1 Mg/kg 1x/week Intravenous Drip). Patient was hospitalized.


6821697-2 | Blood Pressure Increased, Infusion Related Reaction, Stress
on Jun 23, 2010 Female patient from BRAZIL , weighting 47.40 lb, was diagnosed with mucopolysaccharidosis iv and was treated with Naglazyme (View Usage). Patient had the following side effects: blood pressure increased, infusion related reaction, stress (What is stress?). Naglazyme dosage: (4 Vials Intravenous Drip). During the same period patient was treated with POLARAMINE /00072502/ (View Polaramine /00072502/ Review and Polaramine /00072502/ Label ). Patient was hospitalized.

6786907-9 | Bronchospasm, Tachycardia
Patient was taking Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: bronchospasm, tachycardia on Jun 01, 2010 from BRAZIL Additional patient health information: Male patient , weighting 50.27 lb, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: 20 Mg 1x/week Intravenous Drip. Patient was hospitalized.

6786879-7 | Gastric Haemorrhage, Gastritis
Adverse event was reported on Apr 27, 2010 by a Male patient taking Naglazyme (View Usage) (Dosage: 15 Mg 1x/week Intravenous Drip) . Location: TURKEY , weighting 35.27 lb, Patient experienced the following unwanted or unexpected effects: gastric haemorrhage, gastritis. During the same period patient was treated with RANITIDINE (View Ranitidine Review and Ranitidine Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6781105-7 | Pneumonia
on Jun 01, 2010 Male patient from COLOMBIA , weighting 55.12 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient had the following side effects: pneumonia (What is pneumonia?). Naglazyme dosage: 5 Vials Q8d Intravenous Drip. Patient was hospitalized.

6780961-6 | Convulsion, Pneumonia
on Jun 03, 2010 Male patient from COLOMBIA , weighting 41.89 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: convulsion, pneumonia (What is pneumonia?). Naglazyme dosage: (20 Mg 1x/week Intravenous Drip). During the same period patient was treated with AMPICILLIN (View Ampicillin Review and Ampicillin Label ). Patient was hospitalized.

6766702-7 | Infusion Related Reaction
Patient was taking Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: infusion related reaction on May 26, 2010 from BRAZIL Additional patient health information: Female patient , child 8 years of age, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: (intravenous Drip), (20 Mg 1x/week Intravenous Drip). Patient was hospitalized.

6766473-4 | Spinal Cord Compression
Adverse event was reported on May 25, 2010 by a Female patient taking Naglazyme (View Usage) (Dosage: (1 Mg/kg 1x/week Intravenous Drip)) was diagnosed with mucopolysaccharidosis vi and. Location: BRAZIL , weighting 35.27 lb, Patient had the following side effects: spinal cord compression. Patient was hospitalized.

6743290-2 | Chills, Hyperhidrosis, Infusion Related Reaction, Lung Infection Pseudomonal, Oxygen Saturation Decreased, Pulmonary Oedema, Rash, Respiratory Failure, Tachycardia
on May 11, 2010 Male patient from COLOMBIA , weighting 55.12 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: chills, hyperhidrosis, infusion related reaction, lung infection pseudomonal, oxygen saturation decreased, pulmonary oedema, rash (What is rash?), respiratory failure, tachycardia. Naglazyme dosage: 25 Mg 1x/week Intravenous Drip. During the same period patient was treated with PREGABALIN (View Pregabalin Review and Pregabalin Label ), HYDROCORTISONIE (View Hydrocortisonie Review and Hydrocortisonie Label ), LORATADINE (View Loratadine Review and Loratadine Label ). Patient was hospitalized.

6738021-6 | Spinal Operation
on May 11, 2010 Female patient from BRAZIL , child 4 years of age, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: spinal operation. Naglazyme dosage: 3 Vials; Qw; Ivdrp.

6729701-7 | Haemoptysis, Pneumonia Staphylococcal, Post Procedural Haemorrhage, Renal Disorder, Tracheostomy Infection
Patient was taking Naglazyme (View Usage). Patient had the following side effects: haemoptysis, pneumonia staphylococcal, post procedural haemorrhage, renal disorder, tracheostomy infection on Apr 30, 2010 from UNITED STATES Additional patient health information: Female patient , 22 years of age, weighting 155.0 lb, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: 1 Mg/kg;qw;ivdrp. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ). Patient was hospitalized.

6722057-5 | Convulsion
Adverse event was reported on Apr 26, 2010 by a Female patient taking Naglazyme (View Usage) (Dosage: ; Ivdrp) was diagnosed with mucopolysaccharidosis vi and. Location: BRAZIL , 18 years of age, After Naglazyme was administered, patient had the following side effects: convulsion.

6714058-8 | Mitral Valve Incompetence, Respiratory Disorder
on Apr 21, 2010 Female patient from BRAZIL , 14 years of age, weighting 61.73 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: mitral valve incompetence, respiratory disorder. Naglazyme dosage: 4 Vials;qw;ivdrp. During the same period patient was treated with DIGOXIN (CON.) (View Digoxin (con.) Review and Digoxin (con.) Label ), FUROSEMIDE (CON.0 (View Furosemide (con.0 Review and Furosemide (con.0 Label ), CAPTOPRIL (CON.) (View Captopril (con.) Review and Captopril (con.) Label ). Patient was hospitalized.

6713923-5 |
on Apr 21, 2010 Female patient from POLAND , 38 years of age, weighting 88.18 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). . Naglazyme dosage: 40 Mg; Ivdrp.

6710402-6 | Cough, Dyspnoea, Laryngeal Oedema, Malaise, Unevaluable Event
Patient was taking Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: cough, dyspnoea, laryngeal oedema, malaise, unevaluable event on Apr 17, 2010 from SPAIN Additional patient health information: Female patient , child 4 years of age, weighting 37.48 lb, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: 15 Mg; Qw; Ivdrp. During the same period patient was treated with DEXCHLORPHENIRAMINE MALEATE (View Dexchlorpheniramine Maleate Review and Dexchlorpheniramine Maleate Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ).

6704168-3 | Deafness, Disease Recurrence, Otitis Media
Adverse event was reported on Jan 29, 2009 by a Male patient taking Naglazyme (View Usage) (Dosage: 25 Mg; Qw; Ivdrp; See Image) was diagnosed with mucopolysaccharidosis vi and. Location: JAPAN , child 7 years of age, weighting 48.50 lb, Patient experienced the following unwanted or unexpected effects: deafness, disease recurrence, otitis media. Patient was hospitalized.

6701227-6 | Angioedema
on Apr 19, 2010 Male patient from BRAZIL , child 8 years of age, weighting 40.79 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient had the following side effects: angioedema. Naglazyme dosage: 0.8 Mg/kg;qw; Ivdrp; 0.85 Mg/kg;qw; Ivdrp. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6700776-4 | Respiratory Failure
on Apr 13, 2010 Female patient from BRAZIL , 13 years of age, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: respiratory failure. Naglazyme dosage: Qw; Ivdrp, Qw; Ivdrp, Ivdrp. Patient was hospitalized.

6700190-1 | Intracranial Pressure Increased
Patient was taking Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: intracranial pressure increased on Apr 15, 2010 from BRAZIL Additional patient health information: Female patient , 13 years of age, was diagnosed with mucopolysaccharidosis iv and. Naglazyme dosage: Ivdrp. Patient was hospitalized.

6696280-2 | Device Issue, Intracranial Pressure Increased
Adverse event was reported on Apr 08, 2010 by a Female patient taking Naglazyme (View Usage) (Dosage: 4 Vials; Qw; Ivdrp) was diagnosed with mucopolysaccharidosis vi and. Location: BRAZIL , child 11 years of age, Patient had the following side effects: device issue, intracranial pressure increased. Patient was hospitalized.

6694875-3 | Cardiac Failure, Condition Aggravated
on Apr 06, 2010 Female patient from BRAZIL , 13 years of age, weighting 30.20 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: cardiac failure, condition aggravated. Naglazyme dosage: 3 Bottles; Qw; Ivdrip. During the same period patient was treated with DIGOXIN (View Digoxin Review and Digoxin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ).

6691549-X | Antibody Test Abnormal, Condition Aggravated, Glomerulonephritis Membranous, Mucopolysaccharidosis Vi, Nephritic Syndrome, Nephrotic Syndrome
on Apr 08, 2010 Male patient from FRANCE , child 5 years of age, weighting 29.76 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: antibody test abnormal, condition aggravated, glomerulonephritis membranous, mucopolysaccharidosis vi, nephritic syndrome, nephrotic syndrome. Naglazyme dosage: 15 Mg;qe;ivdrp; Qw;ivdrp; 0.3 Mg/kg;qw;ivdrp; 0.5 Mg/kg; Ivdrp. During the same period patient was treated with DOLIPRANE (View Doliprane Review and Doliprane Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), HYDROXYZINE (View Hydroxyzine Review and Hydroxyzine Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ). Patient was hospitalized.

6691392-1 | Carpal Tunnel Syndrome
Patient was taking Naglazyme (View Usage). Patient had the following side effects: carpal tunnel syndrome (What is carpal tunnel syndrome?) on Apr 05, 2010 from BRAZIL Additional patient health information: Female patient , 19 years of age, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: 5 Mg;qw;ivdrp. Patient was hospitalized.

6691384-2 | Device Related Infection, Lung Infection
Adverse event was reported on Apr 06, 2010 by a Male patient taking Naglazyme (View Usage) (Dosage: 4 Vials;qw;ivdrp) was diagnosed with viral infection (What is viral infection?) and. Location: BRAZIL , child 4 years of age, weighting 57.32 lb, After Naglazyme was administered, patient had the following side effects: device related infection, lung infection. Patient was hospitalized.

6691376-3 | Pneumonia
on Apr 01, 2010 Female patient from BRAZIL , 15 years of age, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonia (What is pneumonia?). Naglazyme dosage: Ivdrip. Patient was hospitalized.

6687671-4 | Pneumonia
on Apr 01, 2010 Female patient from BRAZIL , child 9 years of age, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient had the following side effects: pneumonia (What is pneumonia?). Naglazyme dosage: 20 Mg; Qw; Ivdrp.

6686325-8 | Respiratory Failure
Patient was taking Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: respiratory failure on Apr 01, 2010 from BRAZIL Additional patient health information: Male patient , 14 years of age, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: 20 Mg;qw;ivdrp. Patient was hospitalized.

6686288-5 | Intracranial Pressure Increased
Adverse event was reported on Apr 01, 2010 by a Female patient taking Naglazyme (View Usage) (Dosage: 4 Vials;qw;ivdrp) was diagnosed with mucopolysaccharidosis vi and. Location: BRAZIL , child 11 years of age, Patient experienced the following unwanted or unexpected effects: intracranial pressure increased. Patient was hospitalized.

6686275-7 | Crying, Hyperhidrosis, Hypotension, Infusion Related Reaction, Oxygen Saturation Decreased, Skin Discolouration, Tachycardia
on Apr 01, 2010 Male patient from ITALY , weighting 22.05 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient had the following side effects: crying, hyperhidrosis, hypotension, infusion related reaction, oxygen saturation decreased, skin discolouration, tachycardia. Naglazyme dosage: 10 Mg;qw;ivdrp. During the same period patient was treated with TRIMETON /00072502/ (View Trimeton /00072502/ Review and Trimeton /00072502/ Label ).

6686014-X | Cardio-respiratory Arrest, Choking
on Apr 03, 2010 Female patient from SAUDI ARABIA , child 12 years of age, weighting 32.85 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: cardio-respiratory arrest, choking (What is choking?). Naglazyme dosage: 20 Mg; Qw; Ivdrp. During the same period patient was treated with ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), PHENOBARB (View Phenobarb Review and Phenobarb Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), BENADRYL (View Benadryl Review and Benadryl Label ).

6670287-3 | Cardio-respiratory Arrest, Feeling Abnormal
Patient was taking Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest, feeling abnormal on Mar 22, 2010 from BRAZIL Additional patient health information: Female patient , 17 years of age, weighting 52.91 lb, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: 25 Mg; Qw; Ivdrp.

6670286-1 | Condition Aggravated, Epistaxis, Mouth Haemorrhage, Productive Cough, Pulmonary Hypertension
Adverse event was reported on Mar 23, 2010 by a Male patient taking Naglazyme (View Usage) (Dosage: 4 Vials; Qw; Ivdrp) was diagnosed with mucopolysaccharidosis vi and. Location: BRAZIL , child 4 years of age, weighting 57.32 lb, Patient had the following side effects: condition aggravated, epistaxis, mouth haemorrhage, productive cough, pulmonary hypertension (What is pulmonary hypertension?). During the same period patient was treated with BOSENTAN (View Bosentan Review and Bosentan Label ), CAPTOPRIL (View Captopril Review and Captopril Label ), SILDENAFIL (View Sildenafil Review and Sildenafil Label ). Patient was hospitalized.

6660449-3 | Adverse Event, Infusion Related Reaction
on Mar 11, 2010 Female patient from FRANCE , child 8 years of age, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: adverse event, infusion related reaction. Naglazyme dosage: 1 Mg/kg; Qw; Ivdrp. Patient was hospitalized.

6658005-6 | Intracranial Pressure Increased
on Mar 12, 2010 Female patient from BRAZIL , child 11 years of age, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: intracranial pressure increased. Naglazyme dosage: 4 Vials; Qw; Ivdrp.

6652496-2 | Respiratory Disorder
Patient was taking Naglazyme (View Usage). Patient had the following side effects: respiratory disorder on Mar 11, 2010 from BRAZIL Additional patient health information: Female patient , 14 years of age, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: ;ivdrp. Patient was hospitalized.

6652495-0 | Decreased Appetite, Gastric Haemorrhage, Gastrointestinal Haemorrhage, Haematocrit Decreased, Haemoglobin Decreased, Platelet Count Decreased
Adverse event was reported on Mar 11, 2010 by a Male patient taking Naglazyme (View Usage) (Dosage: 15 Mg;qw;ivdrp) was diagnosed with mucopolysaccharidosis vi and. Location: TURKEY , child 4 years of age, weighting 35.27 lb, After Naglazyme was administered, patient had the following side effects: decreased appetite, gastric haemorrhage, gastrointestinal haemorrhage, haematocrit decreased, haemoglobin decreased, platelet count decreased. During the same period patient was treated with ANTIINFLAMMATORY AGENTS (View Antiinflammatory Agents Review and Antiinflammatory Agents Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ). Patient was hospitalized.

6651011-7 | Pneumonia
on Mar 08, 2010 Male patient from COLOMBIA , child 12 years of age, weighting 55.12 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonia (What is pneumonia?). Naglazyme dosage: 5 Vials; Q8d;ivdrp. Patient was hospitalized.

6650043-2 | Angioedema
on Mar 09, 2010 Male patient from BRAZIL , child 8 years of age, weighting 40.79 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient had the following side effects: angioedema. Naglazyme dosage: 0.8 Mg/kg;qw;ivdrp. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6637088-3 | Pneumonia
Patient was taking Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: pneumonia (What is pneumonia?) on Feb 26, 2010 from BRAZIL Additional patient health information: Female patient , 15 years of age, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: Ivdrp. Patient was hospitalized.

6623453-7 | Hernia
Adverse event was reported on Jun 24, 2009 by a Male patient taking Naglazyme (View Usage) (Dosage: 20 Mg; Qw; Ivdrp) was diagnosed with mucopolysaccharidosis vi and. Location: BRAZIL , 14 years of age, weighting 50.71 lb, Patient experienced the following unwanted or unexpected effects: hernia (What is hernia?). Patient was hospitalized.

6613453-5 | Cardiac Arrest, Metabolic Syndrome, Poor Venous Access, Pyrexia, Respiratory Failure
on Feb 12, 2010 Male patient from BRAZIL , child 9 years of age, weighting 39.68 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?), metabolic syndrome (What is metabolic syndrome?), poor venous access, pyrexia, respiratory failure. Naglazyme dosage: 1 Mg/kg;qw;ivdrp.

6609423-3 | Cellulitis, Fall, Femur Fracture, Hip Fracture, Hyperaemia, Limb Injury, Oedema Peripheral
on Feb 11, 2010 Female patient from BRAZIL , 15 years of age, weighting 41.89 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: cellulitis (What is cellulitis?), fall (What is fall?), femur fracture, hip fracture, hyperaemia, limb injury, oedema peripheral. Naglazyme dosage: 15 Mg; Qw; Ivdrp.

6609375-6 | Aspiration Bronchial, Cardio-respiratory Arrest, Electromechanical Dissociation, Hypoxia
Patient was taking Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: aspiration bronchial, cardio-respiratory arrest, electromechanical dissociation, hypoxia on Feb 11, 2010 from BRAZIL Additional patient health information: Female patient , 16 years of age, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: ;ivdrp.

6605001-0 | Lung Disorder, Pneumonia
Adverse event was reported on Feb 05, 2010 by a Female patient taking Naglazyme (View Usage) (Dosage: 19 Mg;qw;ivdrp ; 19 Mg;qw;ivdrp) was diagnosed with mucopolysaccharidosis vi and. Location: BRAZIL , child 12 years of age, weighting 39.68 lb, Patient had the following side effects: lung disorder, pneumonia (What is pneumonia?).

6603016-X | Diarrhoea
on Feb 05, 2010 Male patient from BRAZIL , child 11 years of age, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). After Naglazyme was administered, patient had the following side effects: diarrhoea. Naglazyme dosage: 19 Mg;qw;ivdrp. Patient was hospitalized.

6598035-6 | Asthenia, Cellulitis, Fall, Hip Fracture
on Feb 02, 2010 Female patient from BRAZIL , 15 years of age, weighting 41.89 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, cellulitis (What is cellulitis?), fall (What is fall?), hip fracture. Naglazyme dosage: 15 Mg; Qw; Ivdrp, 15 Mg; Qw; Ivdrp.

6597749-1 | Abdominal Distension, Device Related Infection, Enterococcal Infection, Haematocrit Decreased, Haemoglobin Decreased, Sepsis
Patient was taking Naglazyme (View Usage). Patient had the following side effects: abdominal distension, device related infection, enterococcal infection, haematocrit decreased, haemoglobin decreased, sepsis (What is sepsis?) on Jan 31, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 18.74 lb, was diagnosed with mucopolysaccharidosis vi and. Naglazyme dosage: 10 Mg; Ivdrp. During the same period patient was treated with ALBUTEROL (View Albuterol Review and Albuterol Label ), BUDESONIDE (View Budesonide Review and Budesonide Label ), CAPTOPRIL (View Captopril Review and Captopril Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ), GLYCOPYRROLATE (View Glycopyrrolate Review and Glycopyrrolate Label ), HEPARIN LOCK FLUSH (View Heparin Lock-flush Review and Heparin Lock-flush Label ), LORATADINE (View Loratadine Review and Loratadine Label ), POLYETHYLENE GLYCOL (View Polyethylene Glycol Review and Polyethylene Glycol Label ). Patient was hospitalized.